Render Target: STATIC
Render Timestamp: 2024-10-24T10:49:21.561Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-08-01 15:24:27.893
Product last modified at: 2024-08-14T19:45:07.535Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

DCBLD2 Antibody #4804

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 120
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    DCBLD2 Antibody detects endogenous levels of total DCBLD2 protein.

    Species Reactivity:

    Human, Mouse, Rat

    The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.

    Species predicted to react based on 100% sequence homology:

    Monkey

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human DCBLD2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    DCBLD2 (discoidin, CUB and LCCL domain-containing 2; also known as ESDN and CLCP1) is a type I transmembrane protein that is structurally similar to neuropilin family proteins and contains the longest known amino-terminal secretory signal sequence among eukaryotic proteins (1). Highly expressed in nerve bundles, vascular smooth muscle cells and upregulated following vascular injury, DCBLD2 may be involved in a wide range of functions in the nervous and vascular systems (1,2). Studies have found DCBLD2 to be upregulated in several types of lung cancer with an especially high frequency in metastatic lesions and lymph node metastasis, implicating a role in the process of tumor progression and metastatic capability (3). DCBLD2 has also been identified as part of a complex EGF phosphotyrosine signaling network, serving as a novel tyrosine phosphorylation target of EGF signaling in human cancer cells (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.